Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.37 |
| ▸ | PER2 | O15055 | 1/20 | 0.37 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2528270 | 0.99 | HSD17B10 (0.42) | HSD17B10USP2LMNAKDM4EGAA | |
| SCHEMBL12215816 | 0.96 | PARP1 (0.40) | HSD17B10USP2LMNAKDM4EGAA | |
| SCHEMBL4034829 | 0.94 | PARP1 (0.41) | HSD17B10USP2LMNAKDM4EGAA | |
| Hydrochloric Acid SCHEMBL2527029 | 0.94 | ALDH1A1 (0.40) | HSD17B10USP2LMNAKDM4EGAA | |
| SCHEMBL5528380 | 0.91 | P2RX7 (0.39) | KDM4EGAAALDH1A1SMN1; SMN2PARP1 | |
| Hydrochloric Acid SCHEMBL2524263 | 0.90 | P2RX7 (0.38) | KDM4EGAAALDH1A1ADRA1BPARP1 | |
| SCHEMBL14535433 | 0.81 | HSD17B10 (0.55) | HSD17B10USP2LMNAKDM4EGAA | |
| SCHEMBL9823622 | 0.78 | APOBEC3A (0.47) | HSD17B10KDM4EGAAALDH1A1ADRA1B | |
| SCHEMBL14535278 | 0.78 | ALDH1A1 (0.44) | KDM4EALDH1A1PARP1P2RX7PER2 | |
| SCHEMBL14048348 | 0.77 | HSD17B10 (0.50) | HSD17B10USP2LMNAKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1989141-B | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL MYERS SQUIBB CO | 2010-06-16 | — | — | CN | disclosed |
| US-7511037-B2 | N-[[4-fluoro-2-(5-methy-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4-,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-7491819-B1 | N-[4-Fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1749011-B1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-10-29 | — | — | EP | disclosed |
| CN-1989141-A | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2007-06-27 | — | — | CN | disclosed |
| US-7176196-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1749011-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-02-07 | — | — | EP | disclosed |
| US-7157447-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060276466-A1 | Bicyclic heterocycles as HIV integrase inhibitors | NAIDU B N | 2006-12-07 | — | — | US | disclosed |
| US-20060199956-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-07 | — | — | US | disclosed |
| WO-2005118593-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050267105-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199956-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TYMP, IMPDH1 | HSD17B10 508/4885USP2 4632/4885LMNA 865/4885 |
| US-20060276466-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TYMP, IMPDH1 | HSD17B10 508/4885USP2 4632/4885LMNA 865/4885 |
| US-20050267105-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TYMP, IMPDH1 | HSD17B10 508/4885USP2 4632/4885LMNA 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.